In a nutshell The study evaluated whether Breast Cancer Index (BCI) can predict benefits from extended endocrine therapy (EET) in patients with hormone-receptor-positive (HR+) early-stage breast cancer (BC). The authors found that BCI can predict which patients would benefit from 10 years of EET. Some background Endocrine therapy (ET) prevents tumor...
Read More
In a nutshell This trial was carried out to analyze whether the length of time without treatment and the length of time without active disease influences the survival of patients with advanced breast cancer (ABC) spread to the bone taking palbociclib (Ibrance) plus hormonal therapy (HT). The authors concluded...
Read More
In a nutshell The study evaluated the contribution of chemotherapy on cancer-related cognitive impairment (CRCI) reported by women with early breast cancer. The authors found that chemotherapy added to hormonal therapy caused early and short-term CRCI in such patients, compared to hormonal therapy alone. Some background CRCI refers to problems in...
Read More
In a nutshell The study assessed whether enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) increased overall survival (OS) of patients with nonmetastatic, castration-resistant prostate cancer (CRPC). The study found improved survival in patients with CRPC treated with enzalutamide. Some background ADT is a type of hormonal therapy...
Read More
In a nutshell The study investigated the use of relugolix (Relumina), a hormonal therapy drug, in addition to radiotherapy (RT), in managing prostate cancer. The study found that relugolix was effective in reducing androgen (male sex hormones such as testosterone) levels and well tolerated in these patients. Some background Prostate...
Read More
In a nutshell This phase 2 trial will investigate the effectiveness of Q-122, an experimental drug to treat hot flashes in breast cancer (BC). The main outcome will be the hot flash severity score (HFSS). This trial is recruiting in the United States and Australia. The details Breast cancer (BC) is one of the most common cancers in women....
Read More
In a nutshell This study investigated if abiraterone acetate (Zytiga) and prednisone (Deltasone) added to androgen deprivation therapy (ADT) improve survival in patients with advanced prostate cancer. They found that this combination was effective at improving survival in these patients. Some background...
Read More
In a nutshell This phase 2 trial will evaluate the safety and effectiveness of ribociclib (Kisqali) combined with hormonal therapy in patients with estrogen receptor-positive (ER+) breast cancer (BC). The main outcome will be the number of patients that complete 1 year of treatment and survival without signs of cancer. The trial will...
Read More
In a nutshell This study investigated the effectiveness of exercise therapy to treat joint pain in patients with breast cancer (BC) treated with aromatase inhibitors (AIs). They found that the overall quality of life was improved after 12 months of exercise therapy in these patients. Some background Breast cancer is the most common cancer...
Read More
In a nutshell This study aimed to examine the timing of exercise therapy in patients with prostate cancer taking androgen deprivation therapy (ADT). This study found that starting exercise at the onset of ADT helps preserve muscle mass and bone density. Some background Androgen deprivation therapy (ADT) is a treatment option in...
Read MoreIn a nutshell This study aimed to evaluate whole pelvic radiotherapy (WPRT) compared to prostate only radiotherapy (PORT) with hormonal therapy (HT) before or after radiation for patients with intermediate- or high-risk prostate cancer. This study found that HT before radiotherapy and WPRT had superior long-term survival without cancer growing or...
Read MoreIn a nutshell This trial is examining the safety and effectiveness of cabazitaxel (Jevtana) with abiraterone acetate (Zytiga) compared to abiraterone acetate alone for metastatic (cancer that has spread) castration-resistant prostate cancer (cancer that is no longer responding to hormone therapy). The main outcome measured will be the...
Read More
